October 3, 2007 -- Laiyang Jiangbo Pharmaceuticals of Shandong will effect a reverse merger with Genesis Technology Group, which is listed on the OTC Bulletin Board. In its fiscal 2007, Laiyang Jiangbo earned $22 million on $76 million of revenue. It has assets of $55 million, including cash totaling $17 million. The owners of the parent of Laiyang Jiangbo Pharma will be issued stock equivalent to 75% of the new Genesis Technology, making the transaction worth $81 million to them. More details...
